Weekly Recap: Atebrioz FDA approval and $561.3M cash for Zilurgisertib
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) won FDA approval for Atebrioz for FOP patients 12+, paving the way for an October 2026 U.S. launch and patient access program, while holding $561.3M to fund Zilurgisertib and preparing a Sept. 28 investor call on AZURE-1 brelovitug results.Previous Week Rec…